| High | $5.00 |
|---|---|
| Median | $4.50 |
| Low | $4.00 |
| Average | $4.50 |
| Current Price | $0.41 |
Is COCP stock a good Buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: COCP) stock is to Strong Buy COCP stock.
Will COCP go Up?
Cocrystal Pharma Inc (NASDAQ:COCP) The 2 analysts offering 12-month price forecasts for Cocrystal Pharma Inc have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +1,016.63% increase from the last price of 0.40.
Is Cocrystal Pharma a good Buy?
Cocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Who owns COCP stock?
Top 10 Owners of Cocrystal Pharma IncStockholderStakeShares ownedThe Vanguard Group, Inc.3.33%3,246,128Renaissance Technologies LLC1.75%1,704,328BlackRock Fund Advisors1.12%1,093,827Geode Capital Management LLC0.82%800,6026 more rows
What does COCP company do?
Cocrystal Pharma, Inc. (COCP) We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses.
What is COCP’s average 12-month price target, according to analysts?
Based on analyst ratings, Cocrystal Pharma’s 12-month average price target is $4.50.
What is COCP’s upside potential, based on the analysts’ average price target?
Cocrystal Pharma has 929.75% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the [object Object] tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the [object Object] and follow the analysts of your choice. Visit their profiles for more details a...
Stock Price Forecast
The 2 analysts offering 12-month price forecasts for Cocrystal Pharma Inc have a median target of 4.50, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +781.49% increase from the last price of 0.51.
Analyst Recommendations
The current consensus among 2 polled investment analysts is to Buy stock in Cocrystal Pharma Inc. This rating has held steady since June, when it was unchanged from a Buy rating. Move your mouse over past months for detail
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candidates for further development as oral treatments for COVID-19. CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron Clinical trials with oral program and CDI-45204 inhalation/pulmonary-delivered COVID-19 antiviral candidates expected to begin in 2022 BOTHELL, Wash., Jan.
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range
Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern TimeBOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st, 2021.
What is Cocrystal Pharma?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
What is CC-31244?
The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection.
